How Long Do Rituximab Side Effects Last: A Timeline

Rituximab side effects span a timeline that stretches from minutes to years, depending on which effect you are tracking. Infusion reactions typically peak during the first treatment and fade within hours, but the drug’s deeper impact on the immune system can persist for months or, in some people, many years after the last dose. Understanding which effects belong to which window matters for practical decisions about infection precautions, vaccination timing, and knowing when to call your doctor.

The First Hours: Infusion-Related Reactions

The most common side effects happen while rituximab is being infused or within the first few hours afterward. These infusion-related reactions include fever, chills, nausea, headache, low blood pressure, and sometimes rashes or throat tightness. They are driven partly by the sudden release of signaling molecules as immune cells are disrupted, and partly by direct hypersensitivity. In roughly one in ten patients, these reactions are severe enough to halt treatment altogether.¹

The good news is that infusion reactions tend to be worst during the first dose and become milder with each subsequent infusion. Most resolve within a few hours once the infusion is slowed or stopped and standard supportive medications (antihistamines, acetaminophen, sometimes corticosteroids) are given. If you tolerate the first infusion well, serious reactions on later doses are less likely. One nuance worth knowing: patients being treated for autoimmune diseases like rheumatoid arthritis or lupus tend to experience fewer infusion reactions than patients receiving rituximab for lymphoma, probably because the steroid medications given alongside rituximab in autoimmune treatment dampen the response.²

Weeks to Months: Late-Onset Neutropenia

After infusion reactions have come and gone, a less expected side effect can emerge weeks or even months later: late-onset neutropenia, a drop in neutrophils, the white blood cells that are your front-line defense against bacterial infections. This is distinct from the immediate dip in blood counts that chemotherapy can cause. Late-onset neutropenia typically shows up at least four weeks after the last rituximab dose, with a median onset around three months in one analysis of lymphoma patients. When it does appear, it tends to last a median of about eight weeks before resolving on its own.³

A large study of multiple sclerosis patients on rituximab found the incidence was roughly 10 cases per 1,000 person-years of treatment, so it is not rare but also not something that affects the majority of patients. In that cohort, the median time to a first episode was about a year after the last dose, illustrating how wide the window can be. Most episodes were mild, but about one in twenty cases involved a severe enough neutrophil drop to raise the risk of serious infection. Everyone who developed a severe infection in that study recovered with treatment, including antibiotics and medications that stimulate neutrophil production.⁴

Because late-onset neutropenia can appear well after treatment has ended, routine blood count monitoring is standard practice for months after your last dose. If you develop unexplained fevers or infections during that window, a blood count check is warranted even if the infusion itself was months ago.

The Longer Arc: B-Cell Depletion and Recovery

Rituximab works by targeting CD20, a protein on the surface of B cells, which are the immune cells responsible for producing antibodies. The drug is effective precisely because it wipes out these cells. But the flip side is that your body has to rebuild its B-cell population from scratch, and that process is slow and highly variable from person to person.

In many patients, B cells start to reappear in the blood roughly six to nine months after a single course of treatment. But “reappear” does not mean “fully recovered.” A case series of patients treated with rituximab for kidney and autoimmune diseases found that only about 30% had any measurable B-cell repopulation by four years after their last dose. Even at eight years, fewer than half had recovered. And among those who did show repopulation, their B-cell counts remained extremely low, with a median of just 7 cells per microliter at last follow-up.⁵

These are admittedly patients who received rituximab for autoimmune and kidney diseases, and some had multiple courses. But the finding challenges the assumption that B cells reliably bounce back within a year or two. For some people, the immune system’s ability to regenerate its B-cell compartment is durably impaired. Extended or repeated rituximab treatment stretches out this recovery timeline further, though without necessarily increasing the rate of clinically significant infections in children and adolescents studied so far.⁶

Falling Antibody Levels Over Time

B cells are the factories that produce antibodies, so when B cells are depleted, antibody production eventually drops too. This effect does not happen overnight. Existing antibodies circulate in the blood for weeks to months before they are naturally cleared, so immunoglobulin levels can look normal early on even though the machinery to make new ones has been knocked offline.

Over time, though, levels fall. A 14-year real-world study of patients with neuromyelitis optica spectrum disorders found that average IgG levels started declining significantly after about two years of rituximab treatment and continued dropping at a rate of roughly 2% to 8% per year for the next eight years before leveling off. The proportion of patients with low IgG rose from about 1% after one year of treatment to 41% after 14 years.⁷

Low immunoglobulin levels matter because they leave you more vulnerable to infections, especially respiratory and sinus infections. For patients who develop clinically significant drops, immunoglobulin replacement therapy (regular infusions of pooled antibodies from donors) can substantially reduce infection rates. In one study, the median annual infection rate dropped from about one infection per year to roughly one every eight years after starting replacement therapy, though the rate of severe infections did not fall as clearly.⁸

The practical takeaway is that immunoglobulin monitoring should not stop just because rituximab treatment has ended. Levels can continue to drift downward for years, and catching the decline early opens the door to replacement therapy before recurrent infections become a pattern.

Viral Reactivation Risks

One of the more concerning delayed effects of rituximab is the reactivation of dormant viruses. Hepatitis B is the best-documented example. The virus can lie dormant in liver cells for decades, kept in check by immune surveillance. When rituximab suppresses that surveillance, the virus can begin replicating again, sometimes causing severe liver damage.

The timing is unpredictable. Hepatitis B reactivation has been reported as early as two weeks into rituximab therapy and as late as 55 months (more than four years) after stopping it. The clinical flare of hepatitis often occurs after treatment ends, during the phase when the immune system is reconstituting itself and begins attacking virus-infected cells again.⁹ This is why screening for hepatitis B before starting rituximab is standard practice, and why antiviral prophylaxis may continue long after the last infusion.

A rarer but more devastating viral complication is progressive multifocal leukoencephalopathy (PML), caused by reactivation of the JC virus, which most adults carry harmlessly. PML involves the JC virus destroying the brain’s white matter, and outcomes are grim. In a review of 57 cases among HIV-negative rituximab patients, the median time from the last rituximab dose to PML diagnosis was about five and a half months. The case-fatality rate was 90%, with a median survival of just two months after diagnosis.¹⁰ PML remains extremely rare, but awareness of its symptoms (progressive weakness, vision changes, confusion, and coordination problems) is important during the months following treatment.

The Vaccine Timing Question

One of the most practical side effects of rituximab’s lingering immune suppression is that vaccines often do not work while B cells are depleted. If you receive a vaccine during the window when your B cells are absent or still very low, your body cannot mount a proper antibody response, leaving you unprotected despite having been vaccinated.

Research during the COVID-19 pandemic brought this into sharp focus. Among patients with rheumatic diseases, only about 17% produced detectable antibodies after COVID vaccination when vaccinated within six months of their last rituximab dose. That number climbed to roughly two-thirds when the gap was nine to twelve months.¹¹ A study in dermatology patients similarly found that a nine-month gap between rituximab and vaccination was the threshold at which vaccine responses started to look comparable to those of untreated individuals, coinciding with the return of a specific type of B cell called naïve B lymphocytes.¹²

This has direct implications for planning flu shots, pneumonia vaccines, shingles vaccines, and any other immunizations. If you are on a repeating rituximab cycle, your care team may try to schedule vaccines at least five to six months after your last dose and as far before your next one as possible, targeting that window when some B cells have returned. If you are stopping rituximab, waiting at least nine months before vaccinating gives you the best chance of a meaningful immune response.

Broader Immune Shifts in the Years After Treatment

Rituximab’s effects on the immune system extend beyond just B cells. A five-year prospective study of kidney transplant recipients who received a single pre-transplant dose of rituximab found that it triggered a cascade of compensatory immune changes. B-cell subsets in the blood were profoundly suppressed for at least two years. But in response, the body appeared to upregulate other arms of the immune system: T-cell counts, macrophages, and natural killer cell numbers all rose in the months and years that followed, along with markers of immune activation. The frequency of severe infections was doubled in the first two years compared to patients who had not received rituximab.¹³

This is a transplant-specific setting and does not translate directly to everyone who takes rituximab for autoimmune disease or cancer. But it illustrates a broader point: removing one component of the immune system does not leave everything else unchanged. The immune system rebalances itself in complex ways, and some of those adjustments create their own risks over timescales measured in years, not weeks.

Subcutaneous Versus Intravenous Delivery

Rituximab is available both as an intravenous infusion and, for certain indications, as a subcutaneous injection. The route of administration changes the early side-effect profile in predictable ways. Subcutaneous delivery causes far more local skin reactions at the injection site (redness, pain, and rash) compared to the intravenous form. In the phase 3 SABRINA trial, about 23% of patients receiving the subcutaneous form experienced local reactions versus just 2% of those getting the IV version. These reactions were almost always mild or moderate and became less frequent with each subsequent dose.¹⁴

The subcutaneous route also changes the drug’s absorption pattern. Because the drug diffuses slowly from the injection site into the bloodstream, serum levels rise more gradually than with a direct infusion. This means B-cell depletion may take somewhat longer to reach its full extent with the subcutaneous form, though the downstream side-effect timeline for things like low B cells and infection risk is broadly similar.¹⁵

Biosimilars and Whether the Timeline Changes

Several rituximab biosimilars are now widely used, and a natural question is whether they carry the same side-effect timing. The short answer is yes. A systematic review and meta-analysis comparing biosimilar rituximab to the originator product across rheumatoid arthritis and lymphoma studies found no significant differences in adverse events or in the formation of anti-drug antibodies.¹⁶ Head-to-head trials in follicular lymphoma and pemphigus have confirmed similar safety and efficacy profiles out to a year or more.¹⁷¹⁸ If you have been switched to a biosimilar, the side-effect timeline described throughout this article applies equally.

Rituximab During Pregnancy and Effects on the Newborn

Rituximab crosses the placenta, particularly in the third trimester when antibody transfer from mother to fetus is at its peak. If a pregnant person receives rituximab late in pregnancy, the drug can reach the fetus and deplete neonatal B cells before they have had a chance to develop. In one documented case, a newborn exposed to rituximab in the third trimester had no detectable B cells at birth. However, B-cell levels normalized by six months of age, and the infant mounted adequate vaccine responses by ten months.¹⁹

That relatively quick recovery has been the expected pattern, but emerging evidence suggests it is not universal. A more recent case report described a full-term infant with in-utero rituximab exposure who experienced prolonged suppression of immunoglobulin production and switched memory B cells extending beyond the first year of life, lasting longer than prior reports had suggested.²⁰ The evidence base here is still small, mostly built from individual case reports. But for anyone who is pregnant or planning pregnancy and has recently received rituximab, neonatal immune monitoring is a reasonable precaution, and timing rituximab courses well before a planned pregnancy can reduce fetal exposure.

A Practical Summary of Timing Windows

Because rituximab’s effects unfold over such different timeframes, it helps to think about them in layers rather than expecting a single “all clear” date:

Hours: Infusion-related reactions (fever, chills, nausea) typically resolve within hours of stopping or slowing the infusion.
Weeks to months: Late-onset neutropenia can appear from about four weeks to over a year after the last dose, usually lasting a couple of months.
Months: Viral reactivation risks (hepatitis B, JC virus) are highest in roughly the first six months but have been reported years later.
Months to years: B-cell depletion is profound for at least six to nine months and may persist at some level for years, especially after multiple courses.
Years: Immunoglobulin levels can decline gradually over many years of treatment, and low levels may persist even after rituximab is stopped.
Vaccine window: Vaccine responses are substantially impaired for at least six months after a dose and often remain blunted until nine months or longer.

No single blood test captures all of these effects simultaneously. Monitoring typically involves checking blood counts (to catch neutropenia), B-cell counts or flow cytometry (to track depletion), and immunoglobulin levels (to catch falling antibody production). If you are on long-term rituximab, periodic monitoring of all three gives the clearest picture of where you are on the recovery timeline. Your care team can use that information to adjust dosing intervals, plan vaccinations for maximum effectiveness, and decide whether prophylactic antibiotics or immunoglobulin replacement are warranted.